

Newest data show a 20% complication rate in abandoned noninfected leads

Spectranetics

we get your blood flowing"

"Get the Lead Out..."

Pacemaker lead

TV

Dense scar tissue

Dense scar tissue

The issue with the removal of cardiac leads is the dense scar tissue holding them in place. Before a new pacemaker goes in, old cardiac leads should come out. The potential downside of abandoning old leads is simply too problematic.

A recent study shows a 20% patient complication rate when cardiac leads are left behind, resulting in higher morbidity and cost.¹

"With the lead extraction technique available, the issue of the removal of all unwanted pacemaker leads should be addressed."

It is time to get the lead out.

The FDA's Office of Device
Evaluation, in its annual report
for fiscal year 1998, listed the
SLS as one of the
"Significant Medical
Device Breakthroughs."

These are "...first-of-a-kind, e.g., they use a new technology or energy source, or they provide a major diagnostic/therapeutic advancement such as reducing hospital stays, replacing the need for surgical intervention, reducing time needed for diagnostic determination, etc."



...with the only proven, physician-reviewed Cardiac Lead Removal System (CLeaRS™).

The Spectranetics CLeaRS system uses "cool" ultraviolet excimer laser energy to ablate scar tissue holding problematic cardiac leads in place. The old "rip and tear" mechanical method of cardiac lead removal is very traumatic to the patient and often dangerous.

CLeaRS becomes the gold standard

When introduced in 1998, CLeaRS quickly became the gold standard within the industry. Using CLeaRS resulted in:

 Faster procedures, reducing average procedure times to 1.5 hours from 3.5 hours with mechanical methods.²³

 Better outcomes, reducing complications to 1.4% from 2.5% with mechanical methods.²

 More effective lead removal, increasing success rates to 94% from 65% with mechanical methods.

The gold standard goes platinum


With recent enhancements to the SLS catheter and the LLD traction platform, the CLeaRS gold standard went platinum. Now CLeaRS:

- has an average cardiac lead removal time of 4 minutes.⁴
- has reduced complications to 1.0%.⁴⁵
- is even more successful at 98%.45

Refer your patients to physicians who use CLeaRS, the platinum standard.

There is no safer or more effective way to remove problematic cardiac leads.


Before a new pacemaker or ICD goes in, make sure the old cardiac leads come out.



Pop in this platinum CD

This CD examines the pathology of cardiac lead removal and how CLeaRS works from the patient's point of view. It also contains a bibliography of papers on cardiac lead removal and the CLeaRS technology.

For the CLeaRS centers of excellence nearest you, call + 31 33 43 47 050.



Indications for cardiac lead removal

NASPE: Class 1 (life-threatening)

- Septicemia
- Endocarditis
- Lead migration

NASPE: Class 2 (significant morbidity)

- Pocket infection
- Lead migration and erosion
- Vein thrombosis
- Chronic draining sinus
- · Lead replacement

NASPE: Class 3

- Pain
- Malignancy
- Lead replacement

More than 250 hospitals around the world use CLeaRS technology to remove problematic pacemaker and defibrillator cardiac leads.

Well over 15,000 patients have been successfully treated.

This technology uses the "cool" ultraviolet excimer laser to precisely ablate scar tissue holding cardiac leads in place. It is proven to be successful 98% of the time. 45

When you refer patients to physicians who use CLeaRS, complications diminish and long-term success rates climb.

Bohm, A., et al: Complications Dies to Abendoned Nonnfested Pecemeter Leads: PACE, 24 1721 1724, December 2001

Paging Lead Explant with the Excimer Sheath (PLEXES) clinical trial. FDA panel presentation, 1997.

Committe, P.G. et al. Intravencular Extraction of Chromic Pacermeter Efficiely and Follow-up, PACE Vol. 16, 2333-2336, December 1993.

 23rd NASPE Annual Scientific Session, Abstract: Leed Extraction: Initial Experience Using a New Laser Sheath, Kennergren, C., Tyres, F., May 2002

 Komergren, C., et al. Cardioc Lead Extraction with a Novel Locking Stylet. Journal of Interventional Cardiac Electrophysiology; 4:591–593.
 December 2000

Pathology photos courtery of Dr. Andrew Epstein. Gross and Microscopic Pathological Changes Associated With Northorocotomy Implantiable Defibrillator Lauda, Circulation, 1998, 98:1517–1524

Spectranetics

es det your blood flowing"

Corporate Headquisters
THE SPECTRAMETICS CORPORATION
DR Talletinin Court
Colorado Springs, CO 60507-5186

Colwardo Springs, CO 80907-5186 Tel: 719 003-9333 Cunturies Service Tel: 800-231-0978 Fax: 719-833-8791

SPECTRANE THIS INTERNATIONAL BLV Plearmentariat, 6 • 3823 LA Lecescia Thir Nathorizang Tail + 31 33 43 47 050 Fax + 31 33 43 47 051

www.spectranetics.com

